Investment Banking

Investment Banking 2018-05-11T20:39:19+00:00

Seeing all sides, and knowing what matters.

Sectors of Focus

7 b - Investment Banking
M&A TRANSACTIONS
25 m - Investment Banking
TRANSACTION SIZE
continents - Investment Banking
CONTINENTS

Seeing all sides, and knowing what matters.

Sectors of Focus

icon pharma - Investment Banking
PHARMACEUTICALS
icon services - Investment Banking
PHARMACEUTICAL SERVICES
icon health - Investment Banking
CONSUMER HEALTH & OTC

Typical Transaction

  • Sell-side M&A
  • Capital raising

EXPERIENCE + UNDERSTANDING

The Bourne Partners investment banking team understands opportunities from every angle and we concentrate on what’s important to you.

block-woodward-colbeck

Woodward Pharma Services LLC is a specialty pharmaceutical company focused on acquiring, licensing, and commercializing branded and generic prescription drugs for the U.S. market.  Woodward Pharma provides outsourced marketing, sales, and commercial services for the US pharmaceutical industry.

SECTOR: Specialty Pharma
YEAR: July 2021
DEAL SIZE: $125,000,000
MANDATE TYPE: Capital Raise

block-nuvera-udg

Nuvera Life Science is a consulting company dedicated to helping its clients design, build and manage a seamless patient and HCP treatment experience for rare disease and specialty therapeutics.

SECTOR: Pharma Services
YEAR: May 2021
DEAL SIZE: Up to $36 million
MANDATE TYPE: Company Sell-side

block-ani-novitium

ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company focused on delivering value to our customers by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals.

SECTOR: Generic Pharma
YEAR: March 2021
DEAL SIZE: up to $210,000,000
MANDATE TYPE: Company Buy-side

block-contipi-indegene

ConTIPI Medical, and its associate company ConTIPI Limited provide non-surgical and disposable vaginal solutions for women with various Pelvic Floor Disorders (PFDs).

SECTOR: Medical Device
YEAR: March 2021
DEAL SIZE: Undisclosed
MANDATE TYPE: Commercialization

block-provepharm apollo

Apollo USA is the US subsidiary of Apollo Pharmaceuticals Inc. focused on establishing and commercializing a sterile injectable platform in the US.

SECTOR: Pharma
YEAR: December 2020
DEAL SIZE: Undisclosed
MANDATE TYPE: Company sell-side

block-american injectables new rhein

American Injectables is a US-based sterile injectable manufacturer of parenteral drugs with a world-class facility focused on ready-to-use pre-filled syringes and vials.

SECTOR: Pharma
YEAR: September 2020
DEAL SIZE: $10 million
MANDATE TYPE: Series A Financing

block-ivc acella

International Vitamin Corporation (“IVC”) is an industry leading supplier of vitamins and nutritional/dietary supplement products.

SECTOR: Pharma
YEAR: May 2020
DEAL SIZE: Undisclosed
MANDATE TYPE: Asset Divestiture

block-avista

Avista Pharma Solutions is a contract development, manufacturing, and testing organization.

SECTOR: Pharma Services/CDMO
YEAR: January 2019
DEAL SIZE: $252 million
MANDATE TYPE: Company Sell-side

block-endo

Endo is a specialty pharmaceutical company that sells and manufactures branded and generic pharmaceuticals.

SECTOR: Pharma
YEAR: May 2018
DEAL SIZE: Undisclosed
MANDATE TYPE: Asset Divestiture

block-accelovance

Accelovance is a full service clinical Contract Research Organization focused on vaccine, oncology, and general medicine Phase I-IV programs.

SECTOR: Pharma Services
YEAR: April 2018
DEAL SIZE: $32 million
MANDATE TYPE: Company Sell-side

block-optimal

Optimal Research is a Site Management Organization (SMO) providing clinical site solutions to pharmaceutical and biotech companies, medical device companies, and CROs.

SECTOR: Pharma Services
YEAR: September 2017
DEAL SIZE: Undisclosed
MANDATE TYPE: Company Sell-side

block-prophase

Prophase manufactures, markets, and distributes a range of homeopathic and health care products to general public in the United States.

SECTOR: OTC
YEAR: March 2017
DEAL SIZE: $50 million
MANDATE TYPE: Product Sell-side

CONNECTION + COLLABORATION

We collaborate with industry stakeholders and draw on strong relationships on both the advisory and strategic capital sides.

And we don’t stop until the deal is done.